Bardoxolone methyl- Reata Pharmaceuticals

Drug Profile

Bardoxolone methyl- Reata Pharmaceuticals

Alternative Names: Bard - Reata Pharmaceuticals; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Kyowa Hakko Kirin; Reata Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules; Triterpenes
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Hereditary nephritis; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hereditary nephritis; Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Diabetic nephropathies; Renal failure
  • Discontinued Haematological malignancies; Malignant melanoma; Non-alcoholic steatohepatitis; Pancreatic cancer; Solid tumours; Viral hepatitis

Most Recent Events

  • 06 Nov 2017 Phase-II clinical trials in Renal failure (PO)
  • 06 Nov 2017 Adverse event and efficacy data from the phase II TSUBAKI trial in Diabetic nephropathies released by Reata Pharmaceuticals
  • 03 Nov 2017 Efficacy data meeting the primary endpoint of the phase II portion of a phase II/III trial in Hereditary nephritis released by Reata Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top